Biography:
In 1984 I started the company (Digene) that pioneered HPV testing for cancer using DNA from cervical specimens. It is believed to still be the most widely used DNA test for early detection/prevention of cancer. In 1998 I performed one of the first IO Phase I/II trials; it closed meeting all endpoints and showing variable but sometimes striking cancer reduction without toxicity. I now focus on early detection methods for other cancers and am developing the first system to enrich trans-renal DNA from urine to increase sensitivity and convenience of liquid biopsy testing to complement and/or replace methods using blood.
Evaluation of uProcess for detection of oncogene sequences in buffer and urine by qPCR following 3-minute capture and 5-minute purification procedure
Modeling a novel SMARTer design using an optimizing diagnostic: quantitative evaluation of improved patient outcome and sample size reduction, and implications for lower clinical trial costs and facilitating registration